Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Submitted by
admin
on August 14, 2019 - 11:13am
Source:
Pharmaceutical Business Review
News Tags:
Novartis
Sandoz
biosimilars
Amgen
Enbrel
patents
Erelzi
Headline:
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
snippet:
Novartis’ Sandoz said that it will appeal the ruling of a US district court pertaining to the patent infringement case on Erelzi (etanercept-szzs), the company’s biosimilar to Amgen’s Enbrel (etanercept).
Do Not Allow Advertisers to Use My Personal information
